MBX Biosciences, Inc. Common Stock (MBX) Financials
MBX Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 435.9 million | 26.4 million |
| March 31, 2026 | 452.7 million | 14.9 million |
| Dec. 31, 2025 | 385.1 million | 15.9 million |
| Sept. 30, 2025 | 400.1 million | 12.5 million |
MBX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | -23.5 million | 6.1 million |
| March 31, 2026 | -20.6 million | 5.5 million |
| Dec. 31, 2025 | -19.1 million | 2.7 million |
| Sept. 30, 2025 | -21.9 million | 2.2 million |
MBX Net Income
No data available :(
MBX Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 418.6 million | 2.7 million | 3.3 million |
| March 31, 2026 | 440.0 million | 377000 | 178000 |
| Dec. 31, 2025 | 373.7 million | 424000 | 172000 |
| Sept. 30, 2025 | 391.7 million | - | 623000 |
MBX Shares Outstanding
MBX Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | 901000 | 31.0 million | 9.9 million | - |
| March 31, 2026 | 437000 | 18.5 million | 8.8 million | - |
| Dec. 31, 2025 | 793000 | 19.8 million | 6.0 million | - |
| Sept. 30, 2025 | 399000 | 19.3 million | 4.7 million | - |
MBX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | - | - |
| March 31, 2026 | - | 64000 |
| Dec. 31, 2025 | - | 60000 |
| Sept. 30, 2025 | - | 100000 |
MBX
Price: $67.10
52 week price:
Earnings Per Share: 7.67 USD
P/E Ratio: 4.08
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Market Capitalization: 3.1 billion